The SPAC Path to Public

A Life Science CEO and CFO’s Perspective on the Strategy, Process and Outcome

View the replay of our webinar on the SPAC path for life science companies, including the experience of Gemini Therapeutics, which became public following a $216M SPAC transaction in 2021. Topics included the following:

  • Decision making – the factors that influenced strategy and timing, including prior capital raises and clinical development milestones
  • Preparation and Execution – the timeline, steps and parties involved; anecdotes from the trenches
  • Outcome – life as a public company; advice to other CEOs
  • Demystifying SPACs – the importance of optionality and the viability of this path in the current climate